Who owns NTLA?
Institutional ownership of Intellia Therapeutics Inc. from Form 13F, Q2 2026
328 institutional managers reported holding Intellia Therapeutics Inc. (NTLA) in Form 13F filings for Q2 2026, with 143,986,460 shares worth $2.4B. The largest reported holder was ARK Investment Management LLC. Managers that filed both quarters added a net 33,516,776 shares (+30.4%). 53 opened new positions and 28 sold out.
- Funds holding
- 328
- Value held
- $2.4B
- New / sold out
- 53 / 28
- Net shares, same filers
- +30.4%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of NTLA
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| ARK Investment Management LLC | $286M | 11.7% | 16,875,684 | Added |
| BlackRock, Inc. | $261M | 10.7% | 15,409,023 | Added |
| State Street Corp | $156M | 6.4% | 9,234,987 | Added |
| Vanguard Portfolio Management LLC | $124M | 5.1% | 7,332,401 | Added |
| D. E. Shaw & Co., Inc. | $109M | 4.5% | 6,443,323 | Added |
| Vanguard Capital Management LLC | $102M | 4.2% | 6,028,586 | Added |
| Two Sigma Investments, LP | $88.6M | 3.6% | 5,235,348 | Added |
| FMR LLC | $80.8M | 3.3% | 4,773,034 | Added |
| Ra Capital Management, L.p. | $76.6M | 3.1% | 4,526,926 | New |
| Regeneron Pharmaceuticals, Inc. | $62.7M | 2.6% | 3,702,995 | Unchanged |
| Geode Capital Management, LLC | $61.4M | 2.5% | 3,631,061 | Added |
| Arrowstreet Capital, Limited Partnership | $55.5M | 2.3% | 3,280,760 | Added |
| Amova Asset Management Americas, Inc. | $49.0M | 2.0% | 2,897,529 | Added |
| Sumitomo Mitsui Trust Group, Inc. | $49.0M | 2.0% | 2,897,529 | Added |
| Dimensional Fund Advisors LP | $44.0M | 1.8% | 2,602,944 | Added |
| Goldman Sachs Group Inc | $38.3M | 1.6% | 2,264,471 | Added |
| UBS Group AG | $36.4M | 1.5% | 2,152,912 | Trimmed |
| Voloridge Investment Management, LLC | $35.0M | 1.4% | 2,066,356 | Added |
| Contrarius Group Holdings Ltd | $33.1M | 1.4% | 1,955,228 | Added |
| Jupiter Asset Management LTD | $31.3M | 1.3% | 1,849,507 | Added |
| Morgan Stanley | $29.3M | 1.2% | 1,731,905 | Trimmed |
| Armistice Capital, LLC | $25.4M | 1.0% | 1,500,000 | Added |
| Renaissance Technologies LLC | $23.7M | 1.0% | 1,400,004 | New |
| Northern Trust Corp | $21.5M | 0.9% | 1,272,136 | Added |
| HRT Financial LP | $21.0M | 0.9% | 1,243,317 | Added |
Share of 13F holdings is each fund's shares as a share of the 143,986,460 NTLA shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Ra Capital Management, L.p. New+$76.6M
- BlackRock, Inc. Added+$55.0M
- FMR LLC Added+$45.8M
- ARK Investment Management LLC Added+$40.0M
- State Street Corp Added+$39.1M
- Arrowstreet Capital, Limited Partnership Added+$31.9M
- Renaissance Technologies LLC New+$23.7M
- Ghisallo Capital Management LLC New+$20.3M
- Armistice Capital, LLC Added+$19.7M
- Vanguard Portfolio Management LLC Added+$18.8M
Biggest sellers in Q2 2026
- UBS Group AG Trimmed-$9.1M
- Capital Fund Management S.a. Trimmed-$7.3M
- Bank of America Corp Trimmed-$6.9M
- Jane Street Group, LLC Trimmed-$6.3M
- Morgan Stanley Trimmed-$5.9M
- Citadel Advisors LLC Trimmed-$5.0M
- Gsa Capital Partners LLP Trimmed-$2.8M
- Squarepoint Ops LLC Sold out-$2.7M
- AQR Capital Management LLC Trimmed-$2.3M
- Wasatch Advisors LP Trimmed-$2.3M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $644M and sold $72.7M; 139 added and 78 trimmed.
Schedule 13D and 13G filings on NTLA
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-10STATE STREET CORP SCHEDULE 13G filed by Intellia Therapeutics Inc.Schedule 13G
- 2026-08-07STATE STREET CORP SCHEDULE 13G filed by Intellia Therapeutics Inc.Schedule 13G
- 2026-04-29VANGUARD PORTFOLIO MANAGEMENT LLC SCHEDULE 13G filed by Intellia Therapeutics Inc.Schedule 13G
- 2026-02-09STATE STREET CORP SCHEDULE 13G filed by Intellia Therapeutics Inc.Schedule 13G
- 2025-11-12GOLDMAN SACHS GROUP INC SCHEDULE 13G filed by Intellia Therapeutics Inc.Schedule 13G
- 2025-11-12Contrarius Investment Management Ltd SCHEDULE 13G filed by Intellia Therapeutics Inc.Schedule 13G
- 2025-05-13STATE STREET CORP SCHEDULE 13G filed by Intellia Therapeutics Inc.Schedule 13G
Questions about NTLA ownership
- Who owns NTLA stock?
- 328 institutional investment managers reported NTLA positions in their Form 13F filings for Q2 2026, holding 143,986,460 shares worth $2.4B in total. ARK Investment Management LLC reported the largest position.
- Are funds buying or selling NTLA?
- In Q2 2026, 53 managers opened new NTLA positions, 139 added, 78 trimmed and 28 sold out. Managers that filed in both quarters added a net 33,516,776 shares.
- How current is this NTLA institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to NTLA by CUSIP. Options are left out. NTLA news and filings · NTLA insider trades · Top funds